AmbioPharm and CordenPharma are leveraging an acquisition to bolster U.S. peptide manufacturing capabilities, utilizing facilities in South Carolina and adding capacity in Shanghai.
2 reports, 2 independent
Updated May 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AmbioPharm and CordenPharma are leveraging an acquisition to bolster U.S. peptide manufacturing capabilities, utilizing facilities in South Carolina and adding capacity in Shanghai.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- CordenPharma has appointed Jean-Luc Herbeaux as CEO and successfully acquired AmbioPharm.Sub-event
Acquisition bolsters U.S. peptide manufacturing with facilities in South Carolina and Shanghai.1 source
Keep exploring
The entities involved
-
Shanghai
provincial-level municipality in China